Enterprise Value

487.9M

Cash

182.7M

Avg Qtr Burn

-32.59M

Short % of Float

14.00%

Insider Ownership

2.67%

Institutional Own.

97.60%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2/3

Data readout

Evorpacept (ALX148) + Keytruda Details
Cancer, Platinum-resistant ovarian cancer

Phase 2

Data readout

Evorpacept (ALX148) + Keytruda Details
Head and neck cancer, Cancer

Phase 2

Data readout

Phase 1/2

Data readout

Phase 1

Data readout

Phase 1

Data readout

Failed

Discontinued

Evorpacept (ALX148) + Venetoclax Details
Cancer, Acute myeloid leukemia

Failed

Discontinued

Failed

Discontinued